Cancer Biology · us
Where Are Cancer Cells’ Weaknesses Hidden? Pericentromeric Replication Barriers Increase Sensitivity to PARP Inhibitors
Reducing ESCO2 makes cancer cells more vulnerable to PARP inhibitors even when they retain the homologous recombination repair responses tested. A new study points to replication difficulties at specific chromosomal locations, offering clues for predicting drug responses, but its use in selecting treatments for patients has not been established.
Even when DNA damage is similar, its location may determine whether cancer cells survive. A study conducted by NYU Langone Health in collaboration with Pfizer found that reducing the ESCO2 protein makes DNA replication more prone to stalling in a small number of regions around chromosome centromeres, leaving cancer cells more dependent on PARP-related protective mechanisms and more vulnerable to PARP inhibitors. This adds a perspective focused on “where the damage occurs” to our understanding of cancer cells’ drug sensitivity.
The study was published in Nature Cell Biology on November 5. The team first performed CRISPR screens in breast cancer and small cell lung cancer models, identifying ESCO2 as a factor affecting sensitivity to PARP inhibitors. Subsequent experiments showed that even partially reducing this protein, which helps keep newly replicated chromosomes connected, could increase the sensitivity of colorectal, ovarian, and lung cancer cells to the drugs.
The finding raises an important question: Are there other identifiable cellular vulnerabilities involved in the effects of PARP inhibitors? These drugs are already used for some cancers with BRCA1 or BRCA2 mutations, which may impair the DNA repair process known as homologous recombination. However, cells with reduced ESCO2 retained function in the homologous recombination responses tested in the study, indicating that the drug sensitivity observed here cannot be explained solely by a defect in this repair process.
Using highly sensitive molecular imaging, the researchers observed another layer of changes: reducing ESCO2 increased G-quadruplex structures that impede DNA replication, with the burden concentrated at a small number of replication sites. Some of the more vulnerable regions were in repeat-rich DNA around centromeres. Centromeres and their surrounding regions are closely involved in the proper distribution of chromosomes during cell division, so localized replication errors may also have serious consequences.
Cells normally have a protective response that depends on PARP1 activity and involves TIMELESS, which helps protect DNA replication, and DDX11, an enzyme that can unwind G-quadruplexes. In cells with reduced ESCO2, PARP inhibitors disrupted this response, followed by more G-quadruplexes, reduced DNA synthesis, and increased damage near centromeres. These changes outlined a mechanism linking localized replication barriers to impaired cancer cell survival.
The research team is extending the imaging method to patient-derived cancer cells, hoping to identify patterns of replication stress and DNA damage that could predict treatment responses. However, the evidence currently comes from cancer cell models and is insufficient to support using ESCO2 or related imaging features to guide clinical drug selection. Further development of combination treatments would also require verification of efficacy and safety; the study did not establish that reducing ESCO2 could be used safely in patients.
The value of this work lies in shifting the scale of research on drug responses from the whole cell to specific locations on chromosomes. Whether these locations can serve as reliable biomarkers requires further preclinical and clinical research. The study also disclosed that some authors are current or former Pfizer employees and that the laboratory received support from Pfizer and other organizations. Republication of the official press release provided information for cross-checking, but did not constitute independent validation of the research.